Search Result

Isoforms Recommended:	STAT5

Results for "

STAT5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (5) Akt (2) Apoptosis (20) Aurora Kinase (2) Bcr-Abl (7) c-Kit (3) CDK (4) Dopamine Receptor (5) EGFR (1) Endogenous Metabolite (1) FLT3 (10) GHSR (1) HIV (1) Isotope-Labeled Compounds (1) JAK (15) JNK (1) Ligands for Target Protein for PROTAC (1) p38 MAPK (1) Parasite (3) PDGFR (2) PROTACs (4) RAR/RXR (1) Small Interfering RNA (siRNA) (4) Src (1) STAT (30) Thrombopoietin Receptor (2)
By Research Areas:	Cancer (47) Endocrinology (6) Infection (2) Inflammation/Immunology (12) Neurological Disease (7)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pre-designed siRNA Sets (4) siRNAs (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-102048

STAT5-IN-2 2 Publications Verification	STAT Apoptosis	Cancer
STAT5-IN-2 is a *STAT5* inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect .

HY-101853

STAT5-IN-1 20+ Cited Publications	STAT	Cancer
STAT5-IN-1 is a *STAT5* inhibitor with an IC₅₀ of 47 μM for STAT5β isoform.

HY-124500

AC-4-130 4 Publications Verification	STAT Apoptosis	Cancer
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .

HY-131140

BD750 4 Publications Verification	JAK STAT	Inflammation/Immunology Cancer
BD750, an effective immunosuppressant and a *JAK3/STAT5* inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC₅₀ values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .

HY-P1453A

CMD178 TFA	STAT	Cancer
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-RS13892

STAT5A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
STAT5A Human Pre-designed siRNA Set A contains three designed siRNAs for STAT5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAT5A Human Pre-designed siRNA Set A STAT5A Human Pre-designed siRNA Set A

HY-RS13893

STAT5B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
STAT5B Human Pre-designed siRNA Set A contains three designed siRNAs for STAT5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAT5B Human Pre-designed siRNA Set A STAT5B Human Pre-designed siRNA Set A

HY-RS13894

Stat5b Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Stat5b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat5b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Stat5b Mouse Pre-designed siRNA Set A Stat5b Mouse Pre-designed siRNA Set A

HY-RS13895

Stat5b Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Stat5b Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat5b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Stat5b Rat Pre-designed siRNA Set A Stat5b Rat Pre-designed siRNA Set A

HY-P1453

CMD178	STAT	Cancer
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-Y0493

HODHBt HOOBt	STAT HIV	Infection Cancer
HODHBt (HOOBt) inhibits *STAT5-SUMO* interaction by blocking SUMOylation of phosphorylated *STAT5*. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .

HY-125151

BP-1-108	STAT Apoptosis	Cancer
BP-1-108 is a selective inhibitor of *STAT5* (K_i=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of *STAT5*. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer .

HY-14756

Totrombopag	Thrombopoietin Receptor	Others
Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology .

HY-16975

SH-4-54 10+ Cited Publications	STAT	Cancer
SH-4-54 is a *STAT* inhibitor that binds to STAT3 and STAT5 with K_Ds of 300, 464 nM, respectively.

HY-135041

Totrombopag choline SB-559448 choline	Thrombopoietin Receptor	Others
Totrombopag (SB-559448) choline is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag choline initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag choline can be used to study platelet production and megakaryocyte biology .

HY-153050

JAK-IN-24	JAK	Inflammation/Immunology Cancer
JAK-IN-24 is a JAK inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148813

AK-2292	PROTACs STAT	Cancer
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120604

BVB808 NVP_BVB808	JAK STAT	Cancer
BVB808 (NVP_BVB808) is a selective JAK2 inhibitor with approximately 10-fold selectivity for JAK2 over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of JAK2 and reduces the phosphorylation of *STAT5, thereby blocking the JAK2*-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research .

HY-15312

WP1066 20+ Cited Publications	STAT JAK Apoptosis	Cancer
WP1066 is an inhibitor of JAK2 and *STAT3, and also shows effect on STAT5* and ERK1/2, without affecting JAK1 and JAK3.

HY-12960

SKLB4771 FLT3-IN-1	FLT3 c-Kit Apoptosis	Cancer
SKLB4771 is a potent and selective Flt3 inhibitor with an IC₅₀ value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .

HY-116129

BPR1J-340	FLT3 Apoptosis	Cancer
BPR1J-340 is a potent FLT3 inhibitor with an IC₅₀ of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD ⁺ acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities .

HY-122101

NSC114792	JAK Apoptosis	Cancer
NSC114792 is a selective JAK3 inhibitor. NSC114792 induces apoptosis. NSC114792 decreases the protein expression of p-JAK3 and p-STAT5 .

HY-148748

Butyzamide	JAK STAT p38 MAPK	Others
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay .

HY-169182

AK-068	Ligands for Target Protein for PROTAC	Cancer
AK-068 is a *STAT6* ligand, with a K_i of 6 nM and at least >85-fold binding selectivity over STAT5. AK-068 is a ligand for target protein (STAT6) for PROTAC (HY-169179) .

HY-N0366

Sennoside B 1 Publications Verification	PDGFR	Inflammation/Immunology
Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis .

HY-P10283

S1H	GHSR STAT	Endocrinology
S1H, a mimetic of hGH, is a human growth hormone receptor (hGHR) antagonist. S1H inhibits the interaction of hGH with hGHR. S1H inhibits phosphorylation of STAT5 in cells co-treated with hGH .

HY-118532

Tyrphostin AG30 1 Publications Verification AG30	EGFR	Cancer
Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts .

HY-12987

Pimozide 3 Publications Verification R6238	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a K_i of 39 nM; Pimozide also inhibits *STAT3* and *STAT5*.

HY-108417

Debio 0617B	STAT JAK Bcr-Abl	Cancer
Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34 ⁺ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors .

HY-12987R

Pimozide (Standard) R6238 (Standard)	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide (Standard) is the analytical standard of Pimozide. This product is intended for research and analytical applications. Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a K_i of 39 nM; Pimozide also inhibits *STAT3* and *STAT5*.

HY-13905

Flumatinib mesylate 1 Publications Verification HHGV678 mesylate	Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀ values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model .

HY-12987S1

Pimozide-d5 N-Oxide	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor STAT	Neurological Disease Endocrinology Cancer
Pimozide-d₅ N-Oxide is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2].

HY-107429

Abrocitinib 4 Publications Verification PF-04965842	JAK	Inflammation/Immunology
Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .

HY-12987S

Pimozide-d4 R6238-d₄	Dopamine Receptor Adrenergic Receptor STAT	Neurological Disease Endocrinology Cancer
Pimozide-d₄ is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].

HY-12987S2

Pimozide-d4-1 R6238-d₄-1	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide-d₄-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3][4].

HY-149974

CDK8-IN-13	Apoptosis CDK	Cancer
CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC₅₀ value of 51.9 nM. CDK8-IN-13 induces Apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of *Aurora-kinase-A/B, ABL1, AKT, STAT5* and FLT3**. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-148522

FLT3-IN-18	FLT3	Cancer
FLT3-IN-18 is a potent and selective FLT3 inhibitor with an IC₅₀ value of 0.003 μM. FLT3-IN-18 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-18 inhibits FLT3 and STAT5 phosphorylation. FLT3-IN-18 has the potential for the research of acute myeloid leukemia (AML) .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-107429R

Abrocitinib (Standard)	JAK	Inflammation/Immunology
Abrocitinib (Standard) is the analytical standard of Abrocitinib. This product is intended for research and analytical applications. Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 is a high selective FLT3-ITD degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of FLT3-ITD-positive cells, can down-regulate the phosphorylation of FLT3 and *STAT5*. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-13072B

Cenisertib benzoate AS-703569 benzoate; R-763 benzoate	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of *Aurora-kinase-A/B, ABL1, AKT, STAT5* and FLT3**. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-126675A

AS2863619 2 Publications Verification	CDK STAT	Inflammation/Immunology
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 ⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. *STAT5* activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .

HY-143286A

PF15 TFA	PROTACs FLT3	Cancer
PF15 TFA is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 TFA is a high selective FLT3-ITD degrader，with a DC50 of 76.7 nM. PF15 TFA significantly inhibits the proliferation of FLT3-ITD-positive cells，can down-regulate the phosphorylation of FLT3 and STAT5. PF15 TFA also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-126675

AS2863619 free base 2 Publications Verification	CDK STAT	Inflammation/Immunology
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 ⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. *STAT5* activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .

HY-167692

JI069	Others	Others
JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-13775

XL019 5 Publications Verification	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective JAK2 inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-164469

CHMFL-48	Bcr-Abl Apoptosis STAT	Cancer
CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC₅₀ values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as *STAT5* and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML) .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

439 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 439 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1453A

CMD178 TFA	STAT	Cancer
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-P1453

CMD178	STAT	Cancer
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-P10283

S1H	GHSR STAT	Endocrinology
S1H, a mimetic of hGH, is a human growth hormone receptor (hGHR) antagonist. S1H inhibits the interaction of hGH with hGHR. S1H inhibits phosphorylation of STAT5 in cells co-treated with hGH .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0366

Sennoside B 1 Publications Verification	Quinones Structural Classification Classification of Application Fields Leguminosae Anthraquinones Cassia angustifolia Plants Disease Research Fields Cancer	PDGFR
Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis .

HY-15128

9-cis-Retinoic acid 1 Publications Verification Alitretinoin	Structural Classification Classification of Application Fields Terpenoids Source classification Diterpenoids Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	RAR/RXR Apoptosis Endogenous Metabolite
9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities ^[5].

Species:	Human (2)
Tag:	His (2)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71336

	STAT5B Protein, Human (His) Signal Transducer and Activator of Transcription 5B; STAT5B	Human	E. coli
	The STAT5B protein plays dual roles in signal transduction and transcriptional activation in response to KITLG/SCF and growth factors. STAT5B Protein, Human (His) is the recombinant human-derived STAT5B protein, expressed by E. coli , with C-6*His labeled tag. The total length of STAT5B Protein, Human (His) is 321 a.a., with molecular weight of ~38.0 kDa.

HY-P702987

	STAT5 Protein, Human (sf9, His) STAT5	Human	Sf9 insect cells
	STAT5 Protein, Human (sf9, His) is the recombinant human-derived STAT5, expressed by Sf9 insect cells , with His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12987S

Pimozide-d4
Pimozide-d₄ is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].

HY-12987S2

Pimozide-d4-1
Pimozide-d₄-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3][4].

HY-12987S1

Pimozide-d5 N-Oxide
Pimozide-d₅ N-Oxide is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80904

	STAT5 Antibody MGF; STAT5	WB, ICC/IF, IP	Human, Mouse, Rat
	STAT5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 91 kDa, targeting to STAT5. It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80345

	STAT5a Antibody	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	STAT5a Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 91 kDa, targeting to STAT5a. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

HY-P80346

	STAT5b Antibody	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	STAT5b Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 90 kDa, targeting to STAT5b. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80479

	*Phospho-STAT5* (Tyr694) Antibody (YA145)** STAT5A; STAT5; Signal transducer and activator of transcription 5A	WB, IHC-P, ICC/IF	Human, Rat, Mouse
	Phospho-Stat5 (Tyr694) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 91 kDa, targeting to Phospho-Stat5(Y694). It can be used for WB,IHC-P,IF-Cell assays with tag free, in the background of Human, Rat, Mouse.

HY-P81768

	*Phospho-STAT5(Tyr694) Antibody (YA1513)* STAT5A; STAT5; Signal transducer and activator of transcription 5A	WB, IHC-P	Human, Mouse
	Phospho-STAT5(Tyr694) Antibody (YA1513) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1513), targeting Phospho-STAT5(Tyr694), with a predicted molecular weight of 91 kDa . Phospho-STAT5(Tyr694) Antibody (YA1513) can be used for WB, IHC-P experiment in human, mouse background.